ABSTRACT OF THE DISCLOSURE

The object of the present invention is to provide a pharmaceutical composition for treatment of pruritus not associated with dermal inflammation such as pruritus caused by the decrease of cutaneous barrier function. Particularly, the object of the present invention is to provide a pharmaceutical composition, comprising at least one substances having the inhibitory function of NO activity in vivo, such as the inhibitory activity for NO biosynthesis and/or at least one substances having the eliminating activity for NO and a pharmaceutically acceptable carrier.

Another object of the present invention is to provide a method of treatment of pruritus not associated with dermal inflammation such as pruritus caused by the decrease of skin barrier function. The method comprises the step of administrating the pharmaceutical composition of the present invention.

VGG/vat

VAT IRV1048931.1-*-10/15/01 4:31 PM